Source: International Congress 2016 – Management of dyspnoea and exacerbations in chronic lung diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
David Currow (Daw Park, Australia), David Currow, Magnus Ekström, Belinda Fazekas, John Plummer, Stephen Quinn, Christine McDonald, Meera Agar, Katherine Clark, Simon Eckermann, Amy Abernethy. A phase III, multi-site, randomised, double blind, placebo controlled parallel arm study of daily extended release (ER) morphine for chronic breathlessness. Eur Respir J 2016; 48: Suppl. 60, 4808

Member's Comments

No comment yet.

Related content which might interest you: Effect of borago extract on moderate persistent asthma, a phase two randomized, double blind placebo-controlled clinical trial Source: International Congress 2016 – Asthma management Year: 2016 Efficacy and safety of abediterol (LAS100977) in stable asthma: Phase II, randomized, crossover study Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013 A phase II, randomised, placebo controlled trial of 12 weeks treatment with an oral p38 inhibitor in patients with COPD on a background of ICS/LABA Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 Chinese herbs in treatment of postinfectious cough: A multi-centre, randomized, double-blind, placebo-controlled trial Source: Annual Congress 2013 –New drugs in respiratory medicine Year: 2013 Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial Source: Eur Respir J, 54 (4) 1901030; 10.1183/13993003.01030-2019 Year: 2019 Effect of salmetrol-fluticason combination and tiotropium on clinical and physiological improvement of bronchial anthracofibrosis, a double blind randomized, cross over, placebo controlled, clinical trial. Source: International Congress 2017 – Towards better treatments for lung disease: experimental pharmacology Year: 2017 Medical quality control intervention for COPD patients in China: a cluster randomized, controlled trial Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study Source: Annual Congress 2013 –New bronchodilators for COPD management Year: 2013 “Stepping down” in mild-to-moderate asthmatic children being well controlled while receiving low doses of inhaled corticosteroids (ICS): Daily vs. cyclical ICS administration (prospective, randomized, multicentre, open-label trial) Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013 RCT Abstract - Using a smartphone application in COPD patients to increase physical activity following pulmonary rehabilitation. Results of the AMOPUR Study, a multicenter, randomized, controlled study Source: Virtual Congress 2021 – A multidisciplinary approach to the management of chronic respiratory diseases Year: 2021 Late Breaking Abstract - A randomised, double-blind, placebo controlled, clinical trial evaluating imatinib in patients with severe COVID-19 Source: Virtual Congress 2021 – Late breaking basic and translational science of SARS-Cov2 and COVID-19 Year: 2021 A single centre, double blind, double dummy, placebo controlled, randomized, three period cross-over phase III trial to demonstrate therapeutic equivalence between a generic and branded inhalation product of ipratropium bromide in subjects with Source: Eur Respir J 2001; 18: Suppl. 33, 71s Year: 2001 Efficacy of the Plasma Cluster® device in mild to moderate asthmatic children: A randomized, double-blind, placebo-controlled, proof-of-concept trial Source: Annual Congress 2013 –Asthma treatment and management in children Year: 2013 Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 A randomised, double-blind, placebo-controlled phase 3 study investigating the efficacy of nicotine substitution (NS) on nicotine withdrawal symptoms (NWS) in hospitalised smokers (HS) Source: Annual Congress 2009 - Smoking cessation Year: 2009 Effects of the elastic tape on dyspnea, health status, and health-related quality of life in individuals with COPD: a randomized controlled trial Source: Virtual Congress 2020 – Tapas of respiratory physiotherapy Year: 2020 LATE-BREAKING ABSTRACT: The benefits of [italic]Nigella sativa[/italic] oil supplementation on asthma inflammation: A randomised, double-blind, placebo-controlled, phase II trial Source: International Congress 2016 – Novel strategies on COPD and asthma management Year: 2016 Evaluation of ICS/LABA combination therapy on respiratory function in patients with asthma: Open-label, randomized, cross-over trial. Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Quality of life in patients with COPD and nocturnal supplemental oxygen-therapy: a prospective, placebo-controlled cross-over trial Source: Eur Respir J 2005; 26: Suppl. 49, 289s Year: 2005